EWTX — Edgewise Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1710072 ·
Last close
$33.56
Market Cap
$3.61B
52W High
$39.96
52W Low
$26.82
ADV30
1,216,158
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -54,115,000 | -49,013,000 | 518,522,000 | 33,211,000 | 25,319,000 |
| Dec 2025 | 0 | — | -55,979,000 | -50,216,000 | 552,603,000 | 61,148,000 | 30,346,000 |
| Sep 2025 | 0 | — | -46,858,000 | -40,666,000 | 583,466,000 | 46,003,000 | 24,819,000 |
| Jun 2025 | 0 | — | -42,610,000 | -36,115,000 | 613,334,000 | 43,404,000 | 24,263,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-143,816,000
Investing CF
$-32,790,000
Financing CF
$196,088,000
CapEx
$-256,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.63
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-546,371,000
Inventory
—
Receivables
—
ST Investments
$468,961,000
EBIT TTM
$-191,406,000
Pretax Income TTM
$-167,795,000
Interest Exp TTM
—
Analysts
12
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -191,406,000 | -167,795,000 | 552,603,000 | 30,346,000 | — | -143,816,000 |
| Dec 2024 | 0 | -158,832,000 | -133,813,000 | 486,817,000 | 27,601,000 | — | -109,028,000 |
| Dec 2023 | 0 | -114,357,000 | -100,163,000 | 340,035,000 | 21,205,000 | — | -91,948,000 |
| Dec 2022 | 0 | -71,658,000 | -67,640,000 | 367,101,000 | 20,385,000 | — | -52,635,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.33
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ACAD | ACADIA PHARMACEUTICALS INC | $3.64B | $21.26 | — |
| ERAS | Erasca, Inc. | $3.58B | $11.50 | — |
| VKTX | Viking Therapeutics, Inc. | $3.58B | $30.80 | — |
| ORKA | Oruka Therapeutics, Inc. | $3.56B | $59.06 | — |
| OGN | Organon & Co. | $3.52B | $13.41 | — |
News headlines (Yahoo Finance, 1h cache)
Biotech Fund Sells $44.5 Million Erasca Stake After Massive 700% Rally
2026-05-18 20:00 · Yahoo
Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter
2026-05-17 18:33 · Yahoo
Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally
2026-05-17 18:25 · Yahoo
Erasca Stock Is Up 715%. Here’s Why One Biotech Fund Still Bought $68 Million More
2026-05-17 18:18 · Yahoo
What to Know About This Fund’s $50 Million Exit From Ascendis Pharma
2026-05-14 19:05 · Yahoo
This Fund Has a $75 Million Bet on a Hair Loss Biotech Stock Up More Than 500% Post-IPO
2026-05-14 18:57 · Yahoo
Why This Hedge Fund Added $29 Million to a Cancer Stock Already Up 700%
2026-05-14 18:51 · Yahoo
Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2026
2026-05-12 12:00 · Yahoo
Edgewise Therapeutics' Update for EDG-7500 Could Boost Shares, RBC Says
2026-05-08 17:35 · Yahoo
Do Edgewise Therapeutics' (EWTX) New Stock Grants Clarify or Complicate Its Pipeline Execution Story?
2026-05-07 15:26 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.